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Background {#s1}
==========

Pancreatic cancer is one of the most malignent cancers in the world with a 5-year survival rate of below 5% [@pone.0114616-Jemal1]. Up to now, there is not conventional treatment with a significant impact on the course of pancreatic cancer, so that the prognosis for patients still remains poor. Therefore, identification of the molecular changes underlying this cancer will lay the foundations for improving clinical management and outcomes.

Genomic instability is a characteristic feature of almost human tumors [@pone.0114616-Negrini1]. Copy number changes are frequently found in cancers, and are believed to contribute to the initiation and progression of tumors by amplification and activation of oncogenes or deletion-induced down-expression of tumor suppressor genes. Several previous studies have identified some recurrent chromosome alterations in pacreatic cancer, such as gains on 1q, chromosomes 2, 3 and 5, 7p, 8q, 11q, 12p, 14q, 17q, 19q and 20q, losses on chromosomes 1p, 3p, 6, 8p, 9p, 10q, 13q, 14q, 15q, 17p and 18q, and amplifications of FGFR1, HER2 and DcR3 [@pone.0114616-Harada1], [@pone.0114616-Kitoh1], [@pone.0114616-Harada2], [@pone.0114616-Harada3], [@pone.0114616-Lehnen1], [@pone.0114616-Aumayr1], [@pone.0114616-Zhou1]. However, the available information is still limited, especially for Chinese pancreatic cancer.

The present study identified common gains, losses, amplifications and homozygous deletions in pancreatic cancer. We further evaluated the protein expression level of the copy number-increased genes HMGA2 and PSCA.

Materials and Methods {#s2}
=====================

Study Design {#s2a}
------------

First, the genetic aberrations in pancreatic carcinomas were detected by using Agilent 44K Human Genome CGH microarray and common genomic changes were identified. Then, we validated the protein expression of HMGA2 and PSCA which were located in the common aberration chromosome regions in pancreactic cancer.

Patients and Samples {#s2b}
--------------------

Freshly resected tissues from 93 pancreatic carcinoma patients were collected by the Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China from 2006 to 2008. All the pancreatic cancer patients were treated with radical operation, and none of them received any treatment before surgery. Representative tumor regions were excised by experienced pathologists and immediately stored at −70°C until used. All the samples used in this study were residual specimens after diagnosis sampling. Every patient signed separate informed consent forms for sampling and molecular analysis. Clinical characteristics of patients used in the array CGH study are shown in [Table 1](#pone-0114616-t001){ref-type="table"}. This study was approved by the Ethics Committee of Cancer Institute and Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (No. NCC2013B-30).

10.1371/journal.pone.0114616.t001

###### Clinical Characteristics of 15 Patients Studied by Array CGH.
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  No.     Sex     Age   T   N   M   Grade         Pathology
  ----- -------- ----- --- --- --- ------- -----------------------
  01      Male    73    3   0   0   G2∼G3   Ductal adenocarcinoma
  02      Male    60    3   1   0   G2∼G3   Ductal adenocarcinoma
  03      Male    50    3   1   1    G1     Ductal adenocarcinoma
  04     Female   42    3   1   0    G1     Ductal adenocarcinoma
  05     Female   65    3   0   0   G1∼G2   Ductal adenocarcinoma
  06      Male    64    3   1   0    G2     Ductal adenocarcinoma
  07      Male    40    3   1   0   G2∼G3   Ductal adenocarcinoma
  08     Female   40    3   1   1    G2     Ductal adenocarcinoma
  09      Male    73    3   1   0    G3     Ductal adenocarcinoma
  10      Male    62    3   1   0   G2∼G3   Ductal adenocarcinoma
  11      Male    78    3   1   0   G2∼G3   Ductal adenocarcinoma
  12      Male    43    3   1   0   G2∼G3   Ductal adenocarcinoma
  13      Male    60    3   0   0    G3     Ductal adenocarcinoma
  14     Female   74    3   1   1    G3     Ductal adenocarcinoma
  15     Female   54    3   1   0    G3     Ductal adenocarcinoma

Genomic DNA Extraction {#s2c}
----------------------

Genomic DNA was isolated from tumor tissues using the Qiagen DNeasy Blood & Tissue Kit as described by the manufacturer (Qiagen, Hilden, Germany). Tumor cell content of all the samples was greater than 50% by HE staining.

Array-based CGH {#s2d}
---------------

Array CGH experiments were performed using standard Agilent protocols (Agilent Technologies, Santa Clara, CA). Commercial human genomic DNA (PROMEGA, Warrington, UK) was used as reference. For each CGH hybridization, 500 ng of reference genomic DNA and the same amount of tumor DNA were digested with Alu I and RSA I restriction enzyme (PROMEGA, Warrington, UK). The digested reference DNA fragments were labeled with cyanine-3 dUTP and the tumor DNA with cyanine-5 dUTP (Agilent Technologies, Santa Clara, CA). After clean-up, reference and tumor DNA probes were mixed and hybridized onto Agilent 44K human genome CGH microarray (Agilent) for 40 h. Washing, scanning and data extraction procedures were performed following standard protocols.

Microarray Data Analysis {#s2e}
------------------------

Microarray data were analyzed using Agilent Genomic Workbench (Agilent Technologies, Santa Clara, CA) and BRB-arraytools (<http://linus.nci.nih.gov/BRB-ArrayTools.html>). Agilent Genomic Workbench was used to calculate log~2~ ^ratio^ for every probe and to identify genomic aberrations. Mean log~2~ ^ratio^ of all probes in a chromosome region between 0.25 and 0.75 was classified as genomic gain, \>0.75 as high-level DNA amplification, \<−0.25 as hemizygous loss, and \<−0.75 as homozygous deletion. In pathway enrichment analysis, p-value is calculated for each pathway based on the null distribution obtained by a 1000-time random sampling method.

Real-time PCR {#s2f}
-------------

The PCR reactions were performed in a total volume of 20 µl, including 10 µl of 2XPower SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), 2 µl of cDNA/genomic DNA (5 ng/µl), and 1 µl of primer mix (10 µM each). The PCR amplification and detection were carried out in the ABI 7300 (Applied Biosystems, Warrington, UK) as follows: an initial denaturation at 95°C for 10 min; 45 cycles of 95°C for 15 s and 60°C for 1 min. The relative gene expression or relative copy number of the target gene was calculated using the comparative CT Method by normalized to an endogenous GAPDH. The relative to calibrator was given by the formula 2^−ΔΔCt^. ΔCT was calculated by subtracting the average GAPDH CT from the average CT of the gene of interest. The ratio defines the level of relative expression or relative copy number of the target gene to that of GAPDH. 2^−ΔΔCt^ \>2,0 was set for a target amplification, and 2^−ΔΔCt^ \<0.25 was set for a target homozygous deletion.

Immunohistochemical staining {#s2g}
----------------------------

Formalin-fixed, paraffin-embedded pancreatic tumors were placed on the tissue microarray. For each case the cancer tissues were repeated for three times and adjacent morphologically normal tissues for two times. The slides were deparaffinized, rehydrated, immersed in 3% hydrogen peroxide solution for 10 min, heated in citrate buffer (pH 6) for 25 min at 95°C, and cooled for 60 min at room temperature. The slides were blocked by 10% normal goat serum for 30 min at 37°C and then incubated with mouse monoclonal antibody against HMGA2 (abcam, Cambridge, MA) and rabbit polyclonal antibody against PSCA (abcam, Cambridge, MA) overnight at 4°C. After being washed with PBS, the slides were incubated with biotinylated secondary antibody (diluted 1∶100) for 30 min at 37°C, followed by streptavidin-peroxidase (1∶100 dilution) incubation for 30 min at 37°C. Immunolabeling was visualized with a mixture of 3,3′-diaminobenzidine solution. Counterstaining was carried out with hematoxylin.

Expression level was determined on the basis of staining intensity and percentage of immunoreactive cells. Negative expression (score  = 0) was no or faint staining, or moderate to strong staining in \<25% of cells. Weak expression (score  = 1) was a moderate or strong staining in 25% to 50% of cells. And strong expression (score  = 2) was \>50% of the cells with strong staining.

Statistical Analysis {#s2h}
--------------------

Student\'s t-test and Chi square test were performed with the statistical software SPSS 15.0. The differences were judged as statistically significant when the corresponding two-sided *P* value were \<.05.

Results {#s3}
=======

Gains and Losses in Pancreatic Carcinoma Detected by Array CGH {#s3a}
--------------------------------------------------------------

Fifteen samples of pancreatic carcinoma were analyzed in this study and all of them had genomic changes (Range: 1 to 387). Sixteen gains and thirty-two losses were frequently detected (frequency of gain \>30%, and loss \>60%). The most frequent gains were 8p23.3 (41.7%), 1q44 (40%), 14q32.33 (40%), 19q13.43 (36.7%), 1q21.3 (36%) and 5q31.1--q31.2 (35.6%), and most common losses were 11p15.4 (70.7%), 15q15.1--q21.1 (70%), 3p21.31 (68.9%), 17p13.3--p13.2 (66.7%), 19p13.3--p13.2 (66.7%), 5p13.3 (63.3%), 11p11.2 (63.3%) and 19p13.3--p13.11 (63.3%). GISTIC analysis showed that copy number decrease of APOBEC3A (22q13.1) and APOBEC3B (22q13.1) was significant ([Fig. 1](#pone-0114616-g001){ref-type="fig"} and [Table 2](#pone-0114616-t002){ref-type="table"}).

![Genomic aberrations in pancreatic cancer.\
A. Genome-wide frequency plot of pancreatic cancer by array CGH analysis. Line on the right of 0%-axis, gain; line on the left of 0%-axis, loss. B. Numbers of aberrations in pancreatic cancer. X, number of aberrations; Y, number of cases. C. Gains and losses (HDs) identified by GISTIC.](pone.0114616.g001){#pone-0114616-g001}

10.1371/journal.pone.0114616.t002

###### Genomic Gains and Losses in Pancreatic Cancer.
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                                   region                       
  ------ ---- ------------------ ----------- ----------- ------ -----
  Gain    1         8p23.3         181530      1528274    41.7   14
          2          1q44         245415410   247179291   40.0   29
          3        14q32.33       105354886   106311914   40.0    8
          4        19q13.43       63558788    63784382    36.7   23
          5         1q21.3        150354126   151576549   36.0   41
          6     5q31.1--q31.2     134865707   136298888   35.6   24
          7         2p25.3         764887      3196999    33.3   18
          8         3q26.1        162699470   168905351   33.3   44
          9       4p13--p12       42742952    46671044    33.3   36
          10   5p15.33--p15.31     2209390     6426118    33.3   20
          11    8q24.23--q24.3    139224333   140752139   33.3    7
          12        8q24.3        144974801   145624565   33.3   25
          13        11q25         130772681   133432246   33.3   21
          14       12p13.2        10845519    11358635    33.3   17
          15        16q21         62462977    63621204    33.3   17
          16   20q13.32--q13.33   57782831    59579107    33.3   25
  Loss    1        11p15.4         8754790     9967698    70.7   32
          2     15q15.1--q21.1    38644022    42843706    70.0   122
          3        3p21.31        46978276    49648485    68.9   98
          4     17p13.3--p13.2     769430      5382034    66.7   173
          5     19p13.3--p13.2     2323672    10394642    66.7   322
          6         5p13.3        32069173    32512980    63.3   16
          7        11p11.2        46490905    47989325    63.3   57
          8     19p13.2p13.11     10432688    19687095    63.3   437
          9     1p36.11--p32.3    26563174    51476264    62.2   95
          10       7q11.23        71858992    75893876    62.2   78
          11       1p36.33         1698756     2134018    60.0   11
          12    1q21.2--q21.3     148163183   149900117   60.0   75
          13        3p22.3        32516820    33442286    60.0   18
          14         4p14         39145576    40503807    60.0   28
          15        5q31.1        133588162   133774460   60.0    9
          16        7p22.1         5831281     6406280    60.0   16
          17        9q33.3        126479129   127679820   60.0   29
          18    9q33.3--q34.13    128491637   133095053   60.0   135
          19       10q21.3        69347447    70446758    60.0   31
          20       10q22.1        73557841    74435066    60.0   24
          21       12p11.21       31570586    32645521    60.0   16
          22   12q24.11--q24.13   108870045   111393102   60.0   67
          23       12q24.31       121290368   121666026   60.0   12
          24     16q21--q22.1     65103378    69280309    60.0   183
          25    16q22.3--q23.1    72893640    74235712    60.0   45
          26       17p13.1         6842796     8133829    60.0   92
          27   17q21.2--q21.31    37274288    39139633    60.0   95
          28       19p13.3         529533      557029     60.0    2
          29       19p13.3         633003      806290     60.0   11
          30       19q13.12       40386604    40896554    60.0   29
          31       19q13.12       41089222    42656912    60.0   55
          32       22q13.2        39505050    41219454    60.0   58

Note: 1: when two or more adjacent cytobands have copy number changes at a frequency above 30% (gain) and 60% (loss), the average frequency of these cytobands was calculated and listed.

Amplifications and Homozygous Deletions in Pancreatic Carcinoma Detected by Array CGH {#s3b}
-------------------------------------------------------------------------------------

High-level amplifications were detected at two chromosome regions including 7q21.3--q22.1 and 19q13.2. Homozygous deletions were identified in 1p33--p32.3, 1p22.1, 1q22, 3q27.2, 6p22.3, 6p21.31, 12q13.2, 17p13.2, 17q21.31 and 22q13.1 ([Table 3](#pone-0114616-t003){ref-type="table"}). Especially, cancer gene AKT2 (19q13.2) was amplified in two carcinomas, and CDKN2C (1p33) was homozygously deleted in other two cases. ([Fig. 2](#pone-0114616-g002){ref-type="fig"}). By searching the COSMIC database, we found that amplification of AKT2 was associated with the increased sentitivity to the drug Z-LLNIe-CHO. More interestingly, homozygous deletion of 22q13.1 containing APOBEC3A and APOBEC3B was identified in both GISTIC and Agilent Genomic Workbench analysis ([Fig. 3](#pone-0114616-g003){ref-type="fig"}).

![Amplification of AKT2 and homozygous deletion of CDKN2C in pancreatic cancer.\
A. amplification of AKT2. B. homozygous deletion of CDKN2C. Arrows indicate the position of AKT2 and CDKN2C.](pone.0114616.g002){#pone-0114616-g002}

![Homozygous deletion of APOBEC3A and APOBEC3B in pancreatic cancer.\
Cycles represent the probes of APOBEC3A and APOBEC3B.](pone.0114616.g003){#pone-0114616-g003}

10.1371/journal.pone.0114616.t003

###### High Level Amplifications and Homozygous Deletions in Pancreatic Cancer.
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                               Region                    
  ----- ---- --------------- ----------- ----------- --- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Amp    1    7q21.3--q22.1   97856949    101901147   2   BAIAP2L1, NPTX2, TMEM130, TRRAP, SMURF1, KPNA7, MYH16, ARPC1A, ARPC1B, PDAP1, BUD31, PTCD1, CPSF4, ATP5J2, ZNF789, ZNF394, ZKSCAN5, C7orf38, ZNF655, ZNF498, CYP3A5, CYP3A7, CYP3A4, CYP3A43, OR2AE1, TRIM4, GJC3, AZGP1, ZKSCAN1, ZSCAN21, ZNF3, COPS6, MCM7, AP4M1, TAF6, CNPY4, MBLAC1, C7orf59, C7orf43, GAL3ST4, GPC2, STAG3, GATS, PVRIG, SPDYE3, PMS2L1, PILRB, PILRA, ZCWPW1, MEPCE, C7orf47, LOC402573, TSC22D4, C7orf51, AGFG2, LRCH4, FBXO24, PCOLCE, MOSPD3, TFR2, ACTL6B, GNB2, GIGYF1, POP7, EPO, ZAN, EPHB4, SLC12A9, TRIP6, SRRT, UFSP1, ACHE, MUC17, TRIM56, SERPINE1, AP1S1, VGF, C7orf52, MOGAT3, PLOD3, ZNHIT1, CLDN15, FIS1, RABL5, EMID2, MYL10, CUX1, SH2B2, SPDYE6, PRKRIP1, ORAI2, ALKBH4, LRWD1, POLR2J
         2       19q13.2      45178101    45465385    2                                                                                                                                                                                                                                                                                                                                     PSMC4, ZNF546, ZNF780B, ZNF780A, MAP3K10, TTC9B, CNTD2, AKT2
  HD     1     1p33--p32.3    51208696    51476264    2                                                                                                                                                                                                                                                                                                                                                        CDKN2C, C1orf185, RNF11
         2       1p22.1       93077577    93587765    2                                                                                                                                                                                                                                                                                                                                            RPL5, SNORA66, FAM69A, MTF2, TMED5, CCDC18, DR1
         3        1q22        154178968   154245532   2                                                                                                                                                                                                                                                                                                                                                         RXFP4, ARHGEF2, SSR2
         4       3q27.2       187138113   187416929   2                                                                                                                                                                                                                                                                                                                                                           TRA2B, ETV5, DGKG
         5       6p22.3       16238624    16245913    3                                                                                                                                                                                                                                                                                                                                                                 MYLIP
         6       6p21.31      36466570    36671623    3                                                                                                                                                                                                                                                                                                                                                      PXT1, KCTD20, STK38, SFRS3
         7       12q13.2      54785155    54799394    2                                                                                                                                                                                                                                                                                                                                                         PA2G4, RPL41, ZC3H10
         8       17p13.2       4789213     4819488    2                                                                                                                                                                                                                                                                                                                                                   RNF167, PFN1, ENO3, SPAG7, CAMTA2
         9      17q21.31      41566540    41624530    4                                                                                                                                                                                                                                                                                                                                                               KIAA1267
         10      22q13.1      37689058    37715431    3                                                                                                                                                                                                                                                                                                                                                          APOBEC3A, APOBEC3B

Note: Amp: amplifications. HD: homozygous deletions.

We further selected the amplified genes AKT2 (19q13.2) and MCM7 (7q22.1) and homozygous deleted genes CAMTA2 (17p13.2) and PFN1 (17p13.2) for validation by real-time PCR. In 15 independent validation samples, amplifications of AKT2 and MCM7 were detected in 6 and 9 cases, and homozygous deletions of CAMTA2 and PFN1d in 3 and 1 cases, respectively ([Fig. 4A](#pone-0114616-g004){ref-type="fig"} and [4B](#pone-0114616-g004){ref-type="fig"}). AKT2 and MCM7 were overexpressed, and CAMTA2 and PFN1 were underexpressed in pancreatic cancer tissues than in morphologically normal operative margin tissues ([Fig. 5A](#pone-0114616-g005){ref-type="fig"} and [5B](#pone-0114616-g005){ref-type="fig"}).

![Validation of amplifications and homozygous deletions of candidate genes in independent pacreatic cancer tissues.\
A. amplication of AKT2 and MCM7. B. homozygous deletion of CAMTA2 and PFN1. C. homozygous deletion of APOBEC3A and APOBEC3B. Ratio = (Copy number of candidate gene in tumor tissues)/(Copy number of candidate gene in commercial human genomic DNA).](pone.0114616.g004){#pone-0114616-g004}

![mRNA expression of candidate genes in pancreatic cancer as compared with that in morphologically normal operative margin tissues detected by using Real-time PCR.\
A. Overexpression of AKT2 and MCM7. B. Underexpression of CAMTA2 and PFN1. C. Underexpression of APOBEC3A and APOBEC3B.](pone.0114616.g005){#pone-0114616-g005}

In independent validation samples, APOBEC3A and APOBEC3B were homozygous deleted in 3 and 4 tumors, respectively ([Fig. 4C](#pone-0114616-g004){ref-type="fig"}). The mRNA expression levels of APOBEC3A and APOBEC3B in tumor tissues were significantly lower than in morphologically normal operative margin tissues ([Fig. 5C](#pone-0114616-g005){ref-type="fig"})

Pathways Enriched for Copy Number Alterations {#s3c}
---------------------------------------------

Pathway enrichment analysis using KEGG database was applied to the CGH data. We found that two pathways enriched in genes with gain and that six pathways enriched in genes with loss. The genomic gains in pancreatic carcinoma changed the pathways of gamma-hexachlorocyclohexane degradation and oxidative phosphorylation. However, cyanoamino acid metabolism, glutathione metabolism, atrazine degradation, taurine and hypotaurine metabolism, arachidonic acid metabolism and parkinson\'s disease pathways were changed by the genomic losses ([Table 4](#pone-0114616-t004){ref-type="table"}).

10.1371/journal.pone.0114616.t004

###### Pathways Enriched in Array CGH Data.
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  Change    No.   Pathway                  Description                 No. of genes   *P* value
  -------- ----- ---------- ----------------------------------------- -------------- -----------
  Gain       1    hsa00361   gamma-Hexachlorocyclohexane degradation        24          0.001
             2    hsa00190          Oxidative phosphorylation              112          0.004
  Loss       1    hsa00460         Cyanoamino acid metabolism               9           0.001
             2    hsa00480           Glutathione metabolism                 40          0.001
             3    hsa00791            Atrazine degradation                  7           0.001
             4    hsa00430     Taurine and hypotaurine metabolism           10          0.002
             5    hsa00590         Arachidonic acid metabolism              55          0.005
             6    hsa05020            Parkinson\'s disease                  15          0.007

Validation of HMGA2 and PSCA in Pancreatic Cancer using Immunohistochemistry {#s3d}
----------------------------------------------------------------------------

Copy number increase of HMGA2 and PSCA was detected in one and four tumor, respectively. Because of their significant role in tumorigenesis [@pone.0114616-Ding1], [@pone.0114616-Xi1], [@pone.0114616-Morishita1], [@pone.0114616-Sun1], we analyzed the protein expression of HMGA2 and PSCA using immunohistochemistry (IHC). The results showed that overexpression of HMGA2 and PSCA was detected in 76.7% and 65.0% of pancreatic cancer patients, respectively ([Fig. 6](#pone-0114616-g006){ref-type="fig"}). Further, overexpression of PSCA was significantly associated with lymph node metastasis ([Table 5](#pone-0114616-t005){ref-type="table"}), and overexpression of HMGA2 was significantly associated with invasive depth of pancreatic cancer ([Table 6](#pone-0114616-t006){ref-type="table"}).

![Representative immunohistochemistry results of HMGA2 and PSCA in pancreatic cancer as compared with those in morphologically normal operative margin tissues.\
A. Strong and negative expression of HMGA2. B. Strong and negative expression of PSCA.](pone.0114616.g006){#pone-0114616-g006}

10.1371/journal.pone.0114616.t005

###### Association between PSCA Expression and Clinicopathological Characteristics of the Pancreatic Cancer.
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            PSCA(n = 58)        P value  
  -------- -------------- ---- --------- -------
  Age                            1.53     0.216
  \<60           9         14            
  ≥60            10        25            
  Sex                            0.83     0.362
  Male           13        24            
  Female         6         15            
  pT                             5.19     0.075
  T1             2         0             
  T2             1         6             
  T3             16        33            
  pN                             4.37     0.037
  N0             16        22            
  N1             3         17            
  pM                             0.095    0.758
  M0             16        34            
  M1             3         5             
  Grade                          2.029    0.362
  G1             3         5             
  G2             6         20            
  G3             10        14            

10.1371/journal.pone.0114616.t006

###### Association between HMGA2 Expression and Clinicopathological Characteristics of the Pancreatic Cancer.
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            HMGA2(n = 60)                     
  -------- --------------- ---- ---- -------- -------
  Age                                 3.096    0.213
  \<60            5         14   6            
  ≥60             9         12   14           
  Sex                                 0.754    0.686
  Male           11         17   14           
  Female          3         9    6            
  pT                                  0.785    0.94
  T1              0         1    1            
  T2              2         3    2            
  T3             12         22   17           
  pN                                  13.062   0.001
  N0             10         21   6            
  N1              4         5    14           
  pM                                  1.961    0.375
  M0             10         23   17           
  M1              4         3    3            
  Grade                                6.21    0.184
  G1              1         6    2            
  G2              7         10   9            
  G3              6         10   9            

Discussion {#s4}
==========

Genomic aberrations can contribute to the carcinogenesis and tumor progression. In order to identify DNA copy number changes in pancreatic cancer, we performed array-based comparative genomic hybridization and found that sixteen gains with frequency above 30% and thirty-two losses above 60%, with two high-level amplifications at 7q21.3--q22.1 and 19q13.2 and ten homozygous deletions at 1p33--p32.3, 1p22.1, 1q22, 3q27.2, 6p22.3, 6p21.31, 12q13.2, 17p13.2, 17q21.31 and 22q13.1. By comparing our results with CGH data presented in progenetix web site [@pone.0114616-Baudis1], [@pone.0114616-Baudis2], we found that most genomic aberrations were consistent. But there were still some differences. For example, loss of 9p was more frequent than loss of 9q in progenetix data, but the frequency of 9q loss was higher than 9p loss in our study. The gain of chromosome 7 was very common in progenetix data, but loss of this chromosome was more frequent in our data.

Significantly, cancer gene AKT2 was amplified in two pancreatic cancer patients, and cancer gene CDKN2C was homozygously deleted in other two cases. We validated the amplification of AKT2 and MCM7 (7q22.1) and homozygous deletion of CAMTA2 (17p13.2) and PFN1 (17p13.2) in pancreatic cancer, and further found that AKT2 and MCM7 were overexpressed, and CAMTA2 and PFN1 were underexpressed in pancreatic cancer as compared with those in morphologically normal operative margin tissues. These results suggested that genes including AKT2, MCM7, CAMTA2 and PFN1 might play important roles in pancreatic cancer. Homozygous deletion of CDKN2C has been found in myeloma, and copy number decrease of CDKN2C was significantly associated with a worse overall survival [@pone.0114616-Kulkarni1], [@pone.0114616-Leone1], [@pone.0114616-Boyd1]. However, there was still little information about the role of CDKN2C in pancreatic cancer. Concerning the alteration of AKT2 in human malignancies, Miwa et al. have reported the amplification of AKT2 was in 3 of 12 pancreatic cancer cell lines and in 3 of 20 primary pancreatic carcinomas. Overexpression of AKT2 was also detected in the 3 cell lines with amplified AKT2 [@pone.0114616-Miwa1]. The up-regulation of AKT2 was correlated with the prognosis [@pone.0114616-Nitsche1]. Tanno et al. found that active AKT promoted the invasiveness of pancreatic cancer cells through up-regulating IGF-IR expression [@pone.0114616-Tanno1]. RNAi simultaneously targeting AKT2 and K-ras could inhibite the pancreatic tumor growth [@pone.0114616-Shi1]. Chen et al. demonstrated that AKT2 inhibition could abrogate gemcitabine-induced activation of AKT2 and NF-κB, and promote gemcitabine-induced PUMA upregulation, resulting in chemosensitization of pancreatic tumors to gencitabine [@pone.0114616-Chen1]. Our results further verified the amplification of AKT2 in pancreatic cancer. By searching the COSMIC database, we also found that amplification of AKT2 was associated with the increased sentitivity to the drug Z-LLNIe-CHO. All these results suggested that amplification of AKT2 maybe develop into a biomarker to divide the pancreatic cancer patients into different subgroups for applying different therapy strategy. And in the future, whether the drug Z-LLNIe-CHO could be used to treat the pancreatic cancer patients with AKT2 amplification should be studied.

Interestingly, both GISTIC and Genomic Workbench Software identified 22q13.1 (containing APOBEC3A and APOBEC3B) as homozygous deletion region. Real-time PCR assay showed that APOBEC3A and APOBEC3B were underexpressed in pancreatic cancer tissues than in morphologically normal operative margin tissues. APOBEC enzymes function in innate immune responses, including those that target retroviruses, suggesting links between immunity, mutagenesis and viral infection in the process of cancer development. APOBEC3A could induce hypermutation of genomic DNA and DNA double strand breaks, and catalyze the transition from a healthy to a cancer genome [@pone.0114616-Mussil1], [@pone.0114616-Suspene1]. Pham et al. reported that APOBEC3A was expressed in keratinocytes, and up-regulated in skin cancer [@pone.0114616-Pham1]. APOBEC3B was overexpressed in a majority of ovarian cancer cell lines and high grade primary ovarian cancers. Improtantly APOBEC3B expression was correlated with total mutaion load as well as elevated levels of transversion mutations [@pone.0114616-Leonard1]. Harris et al. reported that APOBEC3B accounted for up to half of the mutational load in breast carcinomas expressing this enzyme [@pone.0114616-Burns1]. In other cancers including bladder, cervix, lung and head and neck, APOBEC3B was also upregulated and its preferred target sequence was frequently mutated and clustered [@pone.0114616-Burns2]. Deletion of APOBEC3B attenuated HBV clearance, and resulted in HBV infection and increased risk for developing hepatocellular carcinoma [@pone.0114616-Zhang1]. Deletion of APOBEC3 was also associated with breast cancer risk among women of European ancestry [@pone.0114616-Xuan1]. Homozygous deletion of APOBEC3B was significantly associated with unfavorable outcomes for HIV-1 acquisition and progression to AIDS [@pone.0114616-An1]. It will be interesting to investigate the role of homozygous deletion of APOBEC3A and APOBEC3B in the pancreatic carcinogenesis.

HMGA2 and PSCA have been reported to be associated with pancreatic cancer. Piscuoglio et al. showed that the percentage of tumor cells with HMGA2 and HMGA1 nuclear immunoreactivity correlated positively with increasing malignancy grade and lymph node metastasis [@pone.0114616-Piscuoglio1], [@pone.0114616-Hristov1]. And HMGA2 maintained oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells [@pone.0114616-Watanabe1]. Our study revealed that gains of HMGA2 and PSCA were detected in one and four pancreatic carcinomas, respectively. In IHC assay, overexpression of HMGA2 was detected in 76.7% and that of PSCA in 65.0% of tumors. And overexpression of PSCA was significantly associated with lymph node metastasis, and overexpression of HMGA2 was significantly associated with invasive depth of pancreatic cancer.

Overall, our study identified multiple copy number-altered chromosome regions in pancreatic cancer. These findings provide important insights into the molecular alterations associated with pancreatic tumorigenesis. Further studies should be conducted to explore the possible tumorigenic roles of these copy number changed genes.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: MRW ZZS. Performed the experiments: JWL ZZS TYS. Analyzed the data: JWL ZZS TYS XC. Contributed reagents/materials/analysis tools: ZW SSS XX YC PZ CFW ZXZ. Wrote the paper: JWL ZZS.
